Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma

Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma NUT midline carcinoma (NMC) is a rare, aggressive poorly differentiated carcinoma genetically defined by NUTM1 gene rearrangement. The purpose of this study was to determine the tumor mutational burden (TMB) and the expression of immunohistochemical (IHC) markers in NMCs that are generally used to identify patients that might benefit from checkpoint immunotherapy. Three cases in a 39-year-old male (case 1) and two 13-year-old females (cases 2, 3) were identified from departmental files, with confirmation by NUT IHC and 15q14 rearrangement by fluorescent in situ hybridization. Normal-tumor paired whole exome sequencing (WES) was applied to determine TMB. IHC for DNA mismatch repair proteins, Programmed cell death ligand 1, programmed cell death 1 (PD1), and CD8 was also performed. WES yielded a TMB of 7.61 and 1.52 per Mbp in the primary and pulmonary metastasis in case 1, respectively, and a TMB of 1.04 per Mbp in the primary tumor of case 2. Programmed cell death ligand 1 tumor proportion score was 20%, 1%, and 0% and combined positive score was 25, 5, and 0 in cases 1, 2, and 3, respectively; PD1 stain counts were 25, 52, and 35 per high-power field and the PD1/CD8 ratio was 95%, 95%, and 99% in cases 1, 2, and 3, respectively. The CD8 count per high-power field was 15, 33, and 30 per high-power field in cases 1, 2, and 3, respectively. Mismatch repair IHCs showed retained staining. Although the number of cases is limited, this study is the first to investigate checkpoint immunotherapy markers in NMCs and the results demonstrate no clear biomarker association. However, the results suggest that, if checkpoint therapy is under consideration, a comprehensive workup utilizing WES and IHC is warranted. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/tumor-mutation-burden-and-checkpoint-immunotherapy-markers-in-nut-g8WffW6A6Z

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000781
Publisher site
See Article on Publisher Site

Abstract

NUT midline carcinoma (NMC) is a rare, aggressive poorly differentiated carcinoma genetically defined by NUTM1 gene rearrangement. The purpose of this study was to determine the tumor mutational burden (TMB) and the expression of immunohistochemical (IHC) markers in NMCs that are generally used to identify patients that might benefit from checkpoint immunotherapy. Three cases in a 39-year-old male (case 1) and two 13-year-old females (cases 2, 3) were identified from departmental files, with confirmation by NUT IHC and 15q14 rearrangement by fluorescent in situ hybridization. Normal-tumor paired whole exome sequencing (WES) was applied to determine TMB. IHC for DNA mismatch repair proteins, Programmed cell death ligand 1, programmed cell death 1 (PD1), and CD8 was also performed. WES yielded a TMB of 7.61 and 1.52 per Mbp in the primary and pulmonary metastasis in case 1, respectively, and a TMB of 1.04 per Mbp in the primary tumor of case 2. Programmed cell death ligand 1 tumor proportion score was 20%, 1%, and 0% and combined positive score was 25, 5, and 0 in cases 1, 2, and 3, respectively; PD1 stain counts were 25, 52, and 35 per high-power field and the PD1/CD8 ratio was 95%, 95%, and 99% in cases 1, 2, and 3, respectively. The CD8 count per high-power field was 15, 33, and 30 per high-power field in cases 1, 2, and 3, respectively. Mismatch repair IHCs showed retained staining. Although the number of cases is limited, this study is the first to investigate checkpoint immunotherapy markers in NMCs and the results demonstrate no clear biomarker association. However, the results suggest that, if checkpoint therapy is under consideration, a comprehensive workup utilizing WES and IHC is warranted.

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Aug 7, 2020

References

  • BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma
  • NUT midline carcinoma
  • Clinicopathologic features and long-term outcomes of NUT midline carcinoma
  • NUT carcinoma in children and adults: a multicenter retrospective study
  • Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck
  • Pediatric NUT-midline carcinoma: therapeutic success employing a sarcoma based multimodal approach
  • Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease
  • The journey from discoveries in fundamental immunology to cancer immunotherapy
  • Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)/PD-L1 blockade: a key player against various cancers
  • The blockade of immune checkpoints in cancer immunotherapy
  • PD-L1 and emerging biomarkers in immune checkpoint blockade therapy
  • Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy
  • Targeting neoantigens to augment antitumour immunity
  • Nuclear protein in testis midline carcinoma misdiagnosed as adamantinoma
  • Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
  • Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer
  • Five-year results in Ewing’s sarcoma. The Scandinavian SarcomaGroup experience with the SSG IX protocol
  • Neoantigens in cancer immunotherapy
  • Genetic basis for clinical response to CTLA-4 blockade in melanoma
  • Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
  • PD-1 blockade in tumors with mismatch-repair deficiency
  • The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer
  • Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
  • Rekindling cancer vaccines
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
  • The landscape of genomic alterations across childhood cancers
  • Tumor mutational burden and driver mutations: further insight into the genomic landscape of pediatric brain tumors
  • Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma
  • FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1
  • Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
  • Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
  • Immune checkpoint inhibition in head and neck cancer